St. Louis Nonprofit Sounds Alarm on Shaky U.S. Drug Lifeline

On March 10, 2026, the API Innovation Center, a St. Louis-based nonprofit, went public with a warning that recurring medicine shortages are not random blips in the system but signs of a structurally fragile U.S. generic drug supply chain. In a new white paper, From Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain, the group says it plans to roll out a National Fragility Index to pinpoint where risks are concentrated and to nudge buyers toward reliability instead of rock-bottom pricing.

The release argues that federal purchasers should start factoring quality and domestic sourcing into their contracts to make private investment in U.S. active pharmaceutical ingredient (API) manufacturing less risky. More than 200 prescription medicines are currently in shortage nationwide, a tally the organization points to as evidence that the system is under serious strain, according to GlobeNewswire.

“Resilience does not happen by accident,” said Tony Sardella, the center’s founder and chair. Kevin Webb, the group’s president and COO, added that “the market must reward reliability, quality and supply security, not just the lowest cost,” comments that underscore the paper’s central claim that it is not only factory capacity that has to change, but also how the government and big buyers pay for generics, per GlobeNewswire.

National Fragility Index: A New Measuring Stick

The paper introduces the National Fragility Index (NFI), a tool the API Innovation Center says will turn vague supply-chain worries into concrete risk scores that can guide both investment and purchasing. In early analysis built on an initial sample of 40 drugs, the index flagged weak spots in anti-infective, oncology, endocrine and cardiovascular medicines, according to the API Innovation Center.

Why Shortage Tallies Disagree

Even counting how many drugs are in shortage is messy. The U.S. Food and Drug Administration’s Drug Shortages database lists dozens of products as “currently in shortage,” while tools used by hospital pharmacists and industry groups often show far more problem drugs. That jumble of lists is exactly what the white paper calls out as a structural flaw: different scorecards mean different priorities. APIIC is urging the creation of a single national reference, or at least harmonized tracking, to give public agencies and private buyers a common playbook, according to the center’s report and related public materials.

How Purchasing Could Change

To move from theory to practice, the white paper outlines procurement reforms such as guaranteed-volume contracts, advance market commitments and longer-term purchasing agreements that would create steadier demand for manufacturers. The idea is to tilt the system away from a pure lowest-price-wins model and toward one that deliberately rewards reliability, quality and supply security, as detailed in the organization’s white paper from the API Innovation Center.

Where Washington Fits In

The issue is already on lawmakers’ radar. APIIC founder Tony Sardella testified before the Senate Special Committee on Aging in October 2025 about vulnerabilities in the drug supply, and senators have floated procurement changes and transparency rules aimed at dialing down reliance on overseas API producers. During a related hearing, Sen. Elizabeth Warren’s office spotlighted the national-security angle and called for stronger moves to shore up domestic manufacturing capacity, according to Sen. Warren’s office.

Why It Matters in St. Louis

For St. Louis, this is not just a policy debate in Washington. The API Innovation Center is based in the city and has teamed up with local partners, including university labs and Missouri manufacturers, to repurpose idle research and factory space for producing critical generic drugs. Coverage of lab renovations and pilot projects around the region highlights how those efforts are being pitched as a blueprint for scaling up domestic API production, per the St. Louis Business Journal.

APIIC says it will keep refining the National Fragility Index and plans to publish more detail on its methodology and expanded findings in the coming months. The group is betting that a clearer picture of risk will help hospitals, federal agencies and private buyers shift from scrambling during shortages to investing ahead of time. Whether long-standing contracting habits will budge remains to be seen, but the paper casts the decision as a choice between short-term savings and long-term national health security.